Principal Financial Group Inc Biotechnology

Principal Financial Group Inc

$172 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
ARDX Ardelyx, Inc.	$804M	$933,000 0.0% of portfolio	135,439	Q3 2024 Reduced 71.27%
CLLS Cellectis S.A.	$89.2M	$873,000 0.0% of portfolio	411,800	Q3 2024 Reduced 5.77%
RPRX Royalty Pharma PLC	$11.5B	$718,000 0.0% of portfolio	25,409	Q3 2024 Reduced 12.72%
RVMD Revolution Medicines, Inc.	$5.04B	$586,000 0.0% of portfolio	12,947	Q3 2024 Reduced 46.55%
IONS Ionis Pharmaceuticals Inc	$5.02B	$525,000 0.0% of portfolio	13,112	Q3 2024 Reduced 24.89%
RNA Avidity Biosciences, Inc.	$2.35B	$461,000 0.0% of portfolio	10,040	Q3 2024 Reduced 39.24%
MDGL Madrigal Pharmaceuticals, Inc.	$5.9B	$345,000 0.0% of portfolio	1,626	Q3 2024 Reduced 46.79%
ACLX Arcellx, Inc.	$3.99B	$335,000 0.0% of portfolio	4,018	Q3 2024 Reduced 89.24%
NUVL Nuvalent, Inc.	$4.11B	$328,000 0.0% of portfolio	3,213	Q3 2024 Reduced 49.19%
MDXG Mimedx Group, Inc.	$1.03B	$327,000 0.0% of portfolio	55,495	Q3 2024 Added 6.31%
AXSM Axsome Therapeutics, Inc.	$4.18B	$304,000 0.0% of portfolio	3,393	Q3 2024 Reduced 48.23%
FOLD Amicus Therapeutics, Inc.	$2.77B	$291,000 0.0% of portfolio	27,275	Q3 2024 Reduced 88.67%
DYN Dyne Therapeutics, Inc.	$1.52B	$269,000 0.0% of portfolio	7,497	Q3 2024 Reduced 45.56%
YMAB Y M Abs Therapeutics, Inc.	$462M	$266,000 0.0% of portfolio	20,294	Q3 2024 New
APLS Apellis Pharmaceuticals, Inc.	$3.58B	$259,000 0.0% of portfolio	9,008	Q3 2024 Reduced 30.09%
PTCT Ptc Therapeutics, Inc.	$3.29B	$247,000 0.0% of portfolio	6,676	Q3 2024 Reduced 45.82%
IDYA Ideaya Biosciences, Inc.	$1.28B	$244,000 0.0% of portfolio	7,720	Q3 2024 Reduced 39.16%
GERN Geron Corp	$1.55B	$225,000 0.0% of portfolio	49,762	Q3 2024 Reduced 45.4%
HRTX Heron Therapeutics, Inc.	$135M	$204,000 0.0% of portfolio	102,651	Q3 2024 Added 456.49%
NVAX Novavax Inc	$684M	$156,000 0.0% of portfolio	12,419	Q3 2024 Reduced 47.37%
RXRX Recursion Pharmaceuticals, Inc.	$1.08B	$146,000 0.0% of portfolio	22,160	Q3 2024 Reduced 37.47%
OCUL Ocular Therapeutix, Inc	$700M	$126,000 0.0% of portfolio	14,561	Q3 2024 Reduced 44.77%
AUPH Aurinia Pharmaceuticals Inc.	$1.24B	$85,000 0.0% of portfolio	11,641	Q3 2024 Reduced 50.66%
ABUS Arbutus Biopharma Corp	$513M	$52,000 0.0% of portfolio	13,755	Q3 2024 Reduced 47.31%
SANA Sana Biotechnology, Inc.	$472M	$51,000 0.0% of portfolio	12,364	Q3 2024 Reduced 52.04%
IBRX Immunity Bio, Inc.	$2.02B	$46,000 0.0% of portfolio	12,513	Q3 2024 Reduced 69.64%
SVRA Savara Inc	$389M	$43,000 0.0% of portfolio	10,188	Q3 2024 Reduced 42.75%
ERAS Erasca, Inc.	$337M	$33,000 0.0% of portfolio	12,381	Q3 2024 Reduced 31.92%
TSHA Taysha Gene Therapies, Inc.	$140M	$31,000 0.0% of portfolio	15,799	Q3 2024 Reduced 26.89%
NUVB Nuvation Bio Inc.	$628M	$28,000 0.0% of portfolio	12,502	Q3 2024 Reduced 51.82%
OCGN Ocugen, Inc.	$199M	$24,000 0.0% of portfolio	25,225	Q3 2024 Reduced 27.02%
AKBA Akebia Therapeutics, Inc.	$353M	$20,000 0.0% of portfolio	15,777	Q3 2024 Reduced 25.27%
NKTR Nektar Therapeutics	$204M	$16,000 0.0% of portfolio	12,455	Q3 2024 Reduced 28.85%
ATOS Atossa Therapeutics, Inc.	$162M	$15,000 0.0% of portfolio	10,245	Q3 2024 Reduced 22.43%
LYEL Lyell Immunopharma, Inc.	$226M	$15,000 0.0% of portfolio	11,213	Q3 2024 Reduced 57.7%
LCTX Lineage Cell Therapeutics, Inc.	$96.8M	$12,000 0.0% of portfolio	13,700	Q3 2024 Reduced 28.93%
XFOR X4 Pharmaceuticals, Inc	$23.3M	$12,000 0.0% of portfolio	18,746	Q3 2024 Reduced 40.32%
VERU Veru Inc.	$55.3M	$10,000 0.0% of portfolio	14,274	Q3 2024 Reduced 13.9%
BLUE Bluebird Bio, Inc.	$27.8M	$6,000 0.0% of portfolio	13,426	Q3 2024 Reduced 53.03%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.